Merck & Co. Inc. (MRK)

84.50
0.18 0.21
NYSE : Health Technology
Prev Close 84.68
Open 84.97
Day Low/High 84.08 / 85.06
52 Wk Low/High 66.10 / 87.35
Volume 2.58M
Avg Volume 8.26M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 214.56B
EPS 2.30
P/E Ratio 39.53
Div & Yield 2.20 (2.59%)
Merck Announces Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019

Merck Announces Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir (MK-8591), the company's investigational nucleoside reverse...

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

Merck Announces Fourth-Quarter 2019 Dividend

Merck Announces Fourth-Quarter 2019 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Merck Presents Early Evidence On Extended Delivery Of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) Via Subdermal Implant

Merck Presents Early Evidence On Extended Delivery Of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) Via Subdermal Implant

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for extended administration of islatravir, the...

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.

Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect

Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect

Sure Petcare, the pet technology specialist, today announced the launch of the SureFeed® Microchip Pet Feeder Connect, the next generation of the best-selling SureFeed Microchip Pet Feeder, which monitors the eating behavior of pets.

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Merck Highlights Commitment To HIV Research With Presentations For Investigational Anti-HIV Agent MK-8591 At IAS 2019

Merck Highlights Commitment To HIV Research With Presentations For Investigational Anti-HIV Agent MK-8591 At IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), are scheduled to be presented at...

FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule For Melanoma And Multiple Other Indications

FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule For Melanoma And Multiple Other Indications

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck Could Push Higher in the Weeks and Months Ahead - $100 Is in the Cards

Merck Could Push Higher in the Weeks and Months Ahead - $100 Is in the Cards

Here's an updated strategy.

Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Merck Gets Boost From Analyst Buy Rating

Merck Gets Boost From Analyst Buy Rating

Shares of pharmaceutical giant Merck gain after Mizuho Securities initiates coverage with a buy rating and a 12-month price target of $97 a share.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #4 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #55 spot out of 500.

Merck To Hold Second-Quarter 2019 Sales And Earnings Conference Call On July 30

Merck To Hold Second-Quarter 2019 Sales And Earnings Conference Call On July 30

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Here's Why I'm Sticking With Merck

Here's Why I'm Sticking With Merck

The charts are saying MRK is ready to rise.

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the...

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients...

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV)...

New Targets for Merck Stock as Charts Point Higher

New Targets for Merck Stock as Charts Point Higher

Investors and traders should approach MRK from the long side.

TheStreet Quant Rating: A (Buy)